Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and treatment-resistant solid tumors.

In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, 3 times weekly intravenous PRP achieved:

  • Greater than 90% mean tumor growth inhibition versus vehicle controls (p < 0.001)
  • Marked reduction in metastatic burden in liver and peritoneum
  • Significant remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of epithelial-mesenchymal transition (EMT) markers
  • Enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, allowing lower chemotherapy doses while improving efficacy
  • Median overall survival extension of more than 2.5-fold in treated animals compared with controls
     

These results are built on previously reported >85% tumor growth inhibition data and peer-reviewed findings on PRP’s impact on PDAC fibroblasts. Translational analyses from limited prior compassionate-use experience with related proenzyme formulations further support a favorable safety profile and signals of prolonged survival in advanced solid-tumor patients.